Exogenous anandamide protects rat brain against acute neuronal injury in vivo

Journal of Neuroscience

Volumn 21, Issue 22, 2001, Pages 8765-8771

  Van Der Stelt, M ^a   Veldhuis, W B ^b,c   Van Haaften, G W ^a   Fezza, F ^d   Bisogno, T ^d   Bar P R ^c   Veldink, G A ^a   Vliegenthart, J F G ^a   Di Marzo, V ^d   Nicolay, K ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d CNR   (Italy)

Author keywords

2 AG; Anandamide; Astrogliosis; Cannabinoid; Excitotoxicity; Ischemia; Magnetic resonance imaging; Neonatal rat; Neuronal injury; Neuroprotection; Ouabain

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ANANDAMIDE; CANNABINOID RECEPTOR ANTAGONIST; OUABAIN; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; EDEMA; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NEWBORN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT;

EID: 0035890082     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.21-22-08765.2001     Document Type: Article

References (65)

1. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain
2. Endocannabinoids control spasticity in a multiple sclerosis model
3. Glutamate release through volume-activated channels during spreading depression
4. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period
5. Biosynthesis, release, and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells
6. Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function
7. A rapid method of total lipid extraction and purification
8. Discovery of a new G-protein-coupled cannabinoid receptor in mouse brain
9. The cannabinoid acids: Nonpsychoactive derivatives with therapeutic potential
10. Ionic dependence of glutamate neurotoxicity
11. Modulation of ion gradients and glutamate release in cultured cerebellar granule cells by ouabain
12. Single-shot diffusion trace 1H NMR spectroscopy
13. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: First inhibitors of anandamide uptake with negligible capsaicin-like activity
14. Status of the neonatal rat brain after NMDA-induced excitotoxic injury as measured by MRI, MRS, and metabolic imaging
15. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
16. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain
17. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
18. Leptin-regulated endocannabinoids are involved in maintaining food intake
19. Pathobiology of ischaemic stroke: An integrated view
20. The role of excitotoxicity in neurodegenerative disease: Implications for therapy
21. Cytokines, inflammation, and brain injury: Role of tumor necrosis factor-α
22. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation
23. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
24. Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo
25. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission
26. Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azideinduced toxicity in cultured neocortical neurons
27. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death
28. Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: Proposed role in neurotoxicity
29. Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity
30. N-Acylethanolamines, precursor phospholipids: Relation to cell injury
31. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor
32. Cellular signal transduction by anandamide and 2-arachidonoylglycerol
33. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons
34. Estrogen as a neuroprotectant in stroke
35. CB1 cannabinoid receptor induction in experimental stroke
36. Isolation, identification, and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding
37. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue postmortem but is contained at low levels in or is absent from fresh tissue
38. 2+-dependent and -independent mechanisms
39. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells
40. Cardiovascular effects of endocannabinoids: The plot thickens
41. Inhibition of sodium-potassium-ATPase: A potentially ubiquitous mechanism contributing to central nervous system neuropathology
42. Brain lesions induced by specific and nonspecific inhibitors of sodium-potassium ATPase
43. The sodium-potassium ATPase inhibitor ouabain is neurotoxic in the rat substantia nigra and striatum
44. The neurotoxicity of ouabain, a sodium-potassium ATPase inhibitor, in the rat hippocampus
45. The effect of A-9-tetrahydrocannabinol on forebrain ischemia in rat
46. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures
47. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals
48. Pharmacology of cannabinoid CB1 and CB2 receptors
49. Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector
50. Endocannabinoids: A new class of vasoactive substances
51. Oxidative damage in the central nervous system: Protection by melatonin
52. A model of transient unilateral focal ischemia with reperfusion in the P7 neonatal rat: Morphological changes indicative of apoptosis
53. N-acylated glycerophospholipids and their derivatives
54. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity
55. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
56. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats
57. A second endogenous cannabinoid that modulates long-term potentiation
58. +-ATPase in neuro-glial cell cultures of cerebellum induces glutamate-dependent damage of granule cells
59. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
60. Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain
61. 9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity
62. Early evolution and recovery from excitotoxic injury in the neonatal rat brain: A study combining magnetic resonance imaging, electrical impedance, and histology
63. Experimental biology of cerebral hypoxia-ischemia: Relation to perinatal brain damage
64. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes
65. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses